NICE Systems Stock Slides 38.5% Despite Operational Gains as Major Investor Reduces Position

The Motley FoolThe Motley Fool
|||1 min read
Key Takeaway

Major investor Black Creek liquidated $32.75M in NICE Systems shares despite strong operational performance, including 49% AI revenue growth and 6% overall revenue expansion.

NICE Systems Stock Slides 38.5% Despite Operational Gains as Major Investor Reduces Position

Black Creek Investment Management liquidated approximately 271,072 shares of NICE Systems in the fourth quarter of 2025, representing a $32.75 million transaction that reduced the fund's stake to 3.28% of assets under management. The divestment comes amid a significant year-long decline in NICE's share price, which has fallen 38.5% and underperformed the broader S&P 500 by 51.42 percentage points.

The sell-off appears disconnected from the company's underlying business performance. NICE delivered 6% year-over-year revenue growth in recent periods, while its cloud revenue segment accelerated at 13% YoY. More notably, the company's artificial intelligence annual recurring revenue demonstrated robust expansion at 49%, indicating strong momentum in high-margin, technology-intensive offerings that align with current market demand.

Analysts suggest the fund's decision may reflect portfolio rebalancing or shifting risk preferences rather than deteriorating fundamentals at NICE. The divergence between the stock's performance and the company's operational metrics underscores the complex dynamics between market sentiment and business execution in the software sector, where investor appetite for growth-stage technology investments has remained volatile.

Source: The Motley Fool

Back to newsPublished Feb 14

Related Coverage

GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR
GlobeNewswire Inc.

Pomerantz Files Securities Fraud Suit Against $INO Over FDA Approval Misstatements

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

INO